Compare Gilead Sciences, Inc. (GILD) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sirius XM Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $151 (market cap $182.40B), while Sirius XM Holdings Inc trades at $26.73 (market cap $8.87B). The key difference: Gilead Sciences, Inc. is far larger — about 20.6× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (4.1%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Sirius XM Holdings Inc for 102 Days on average.
| GILD | SIRI | |
|---|---|---|
Market Cap | $182.40B | $8.87B |
Volume | 4,469,821 | 4,324,672 |
Sector | Health | Media |
52-Week High | $155.80 | $32.59 |
52-Week Low | $116.74 | $19.92 |
Typical Hold Time | 111 Days | 102 Days |
Enterprise Value | $205.46B | $18.16B |
Dividend Yield | 2.23% | 4.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Sirius XM (SIRI) trades at $26.67, up 2.77% today, with mixed technical signals showing neutral momentum. The stock shows attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, while recent earnings have been inconsistent with two misses and one beat in the last three quarters. The company maintains solid profitability with 47.36% gross margins and positive cash flow generation, supported by recent strategic initiatives including YouTube partnerships and advertising expansion.
The investment case balances value appeal against execution risks. Analyst consensus remains bullish with a $34.43 price target (29% upside), though investors face risks from competitive pressures and inconsistent earnings performance. The company's strong cash flow and strategic partnerships provide growth catalysts, but requires monitoring of subscription trends and advertising revenue execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
